A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges.

Cancers (Basel) · 2022 · PMC9454629 · PMID 36077703

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a retrospective analysis, AML patients, less than 60 years old, who underwent allogeneic HSCT had a trend toward improved relapse-free survival (RFS), OS, and a lower relapse rate than their non-transplanted counterparts, but the results did not reach statistical significance [ 33 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.